David B. Rein

Principal Research Scientist

Public Health Research

PhD, Public Policy, Joint PhD Program, Georgia Institute of Technology and Georgia State University
MPA, Public Policy, Wagner School of Government, New York University
BA, Urban Studies, New York University

David B. Rein, Ph.D., is a Principal Research Scientist in NORC’s Public Health Research Division. He specializes in health economics and outcomes research with a particular focus on burden of disease studies and cost-effectiveness simulations. Rein has developed content expertise in the areas of the epidemiology of vision-threatening diseases, viral hepatitis, and vaccination policy. Rein is currently the project director for the BEST-C Hepatitis C Prospective Screening Intervention Evaluation for the CDC’s Division of Viral Hepatitis and is the Principal Investigator of a grant exploring the impact of population differences on visual health screening outcomes for the National Eye Institute, a member institute of the NIH.

Prior to joining NORC, Rein worked as a Research Economist for Research Triangle Institute(RTI) International in the Public Health Economics Program. While there, Rein directed projects and grants for the Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), National Institutes of Health (NIH), Health Resources and Services Admnistration (HRSA), and the Gates Foundation. He was the Project Director of the CDC School Located Vaccination Evaluation (SoLVE) study, a $4.5 million, 2.5 year effort to evaluate influenza vaccination in schools. Dr. Rein started his career in Public Health as an Oak Ridge Institute in Science and Engineering (ORISE) Fellow at the US Centers for Disease Control and Prevention.

Rein is an author of more than 30 publications and book chapters in journals such as The Lancet, Health Services Research, and The American Journal of Public Health. His work evaluating the cost-effectiveness of expanding childhood vaccination against hepatitis A published in Pediatrics was used by the U.S. Advisory Committee on Immunization Practices in their decision to recommend vaccination against hepatitis A nationwide. He has presented internationally on health economics topics in the Argentina, Canada, Germany, and South Korea, in addition to numerous presentations in the United States.

David B. Rein is a Principal Investigator for the National Institutes of Health, received an Agency for Healthcare Research and Quality Grant for Health Services Dissertation Research. He serves as a Consulting Editor to Evaluation Review. While in graduate school, Rein was awarded the Faculty Award presented by the faculty of the School of Public Policy to the top 2003 Ph.D. student in public policy at the Georgia Institute of Technology, as well as the William H. Read Award given to the top 1999 Ph.D. student in public policy in the Joint Program in Public Policy awarded by the Georgia Institute of Technology and Georgia State University.

Representative Projects

Birth Cohort Evaluation to Advance Screening and Testing for Hepatitis C (Best-C). The Birth Cohort Evaluation to Advance Screening and Testing for Hepatitis C (Best-C) will estimate the effectiveness and cost of a Hepatitis C Virus (HCV) screening strategy that targets all individuals in the birth cohorts born between 1945 and 1965 as compared with the current risk-based HCV screening approach. Best-C consists of two studies, a retrospective and a prospective study, where qualitative interviews will assess the feasibility and acceptance of the new (birth-cohort) strategy by medical staff and a simulation model will estimate the cost effectiveness of the birth-cohort screening compared to the risk-based screening.  More

Headlines

Press Release NORC Opens New Offices in Atlanta More
Posted: 4.16.2012 4:16PM
Press Release Over 20 Million Individuals Infected with Hepatitis E in Asia and Africa More
Posted: 3.27.2012 1:27PM
News MedPage Today: Considering the dangers of Hepatitis C, with research and findings from NORC Expert David Rein More
Posted: 2.21.2012 4:50PM
Press Release NORC Opens New Offices More
Posted: 2.21.2012 2:54PM
Press Release Birth Cohort Screening for Hepatitis C is Cost Effective More
Posted: 11.8.2011 10:42AM

Contact